All In MedTech

FDA Clearance Tracker · P030017-S381

WaveWriter Alpha SCS System, WaveWriter Alpha Prime SCS System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 17, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 17, 2025

Approved

Time to decision

87 days

Received Dec 20, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P030017-S381
Device name
WaveWriter Alpha SCS System, WaveWriter Alpha Prime SCS System
Applicant location
Valencia, CA
Received
Dec 20, 2024
Decided
Mar 17, 2025
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P030017

Device type

Device class
Class III

Every decision under product code LGW

FDA's approval statement

As written in FDA's record.

Approval of PMA 180-day supplement, which requested approval for adding 3T Magnetic Resonance (MR) conditional labeling to the implanted components of the WaveWriter Alpha Spinal Cord Stimulation (SCS) System and WaveWriter Alpha Prime SCS System for head and lower extremities

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.